Compare Invesco S&P 500 High Div Low Volatility ETF (SPHD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 High Div Low Volatility ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Invesco S&P 500 High Div Low Volatility ETF trades at $48.79 (market cap $3.14B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 40.6× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Invesco S&P 500 High Div Low Volatility ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 High Div Low Volatility ETF for 125 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SPHD | VRTX | |
|---|---|---|
Market Cap | $3.14B | $127.55B |
Volume | 1,461,349 | 1,487,944 |
52-Week High | $53.55 | $557.96 |
52-Week Low | $46.96 | $407.37 |
Typical Hold Time | 125 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPHD trades at $48.71, up 1.08% with a bearish technical outlook showing 17 sell signals versus 4 buys. The ETF focuses on high dividend yield and low volatility S&P 500 stocks, offering monthly income distribution. Recent dividend payments of $0.20-$0.21 demonstrate consistent income generation, though technical indicators suggest near-term pressure.
While SPHD provides attractive monthly dividends for income-focused investors, the bearish technical signals and concerns about total return performance compared to peers like SCHD present near-term headwinds. The fund's low volatility mandate may provide defensive positioning during market uncertainty, but investors should weigh income benefits against potential capital appreciation limitations.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
